CN107257676A - 生发剂或膳食补充剂 - Google Patents
生发剂或膳食补充剂 Download PDFInfo
- Publication number
- CN107257676A CN107257676A CN201580076883.7A CN201580076883A CN107257676A CN 107257676 A CN107257676 A CN 107257676A CN 201580076883 A CN201580076883 A CN 201580076883A CN 107257676 A CN107257676 A CN 107257676A
- Authority
- CN
- China
- Prior art keywords
- baldness
- dietary supplements
- preparation
- foregoing
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000004384 Alopecia Diseases 0.000 title claims abstract description 107
- 238000002360 preparation method Methods 0.000 title claims abstract description 102
- 230000003676 hair loss Effects 0.000 title claims abstract description 98
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 74
- 239000000203 mixture Substances 0.000 claims abstract description 59
- 239000000463 material Substances 0.000 claims abstract description 45
- 238000012360 testing method Methods 0.000 claims abstract description 17
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000011701 zinc Substances 0.000 claims abstract description 16
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 16
- 235000016804 zinc Nutrition 0.000 claims abstract description 16
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 12
- 239000011575 calcium Substances 0.000 claims abstract description 12
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229910052802 copper Inorganic materials 0.000 claims abstract description 11
- 239000010949 copper Substances 0.000 claims abstract description 11
- 235000016709 nutrition Nutrition 0.000 claims abstract description 11
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000005259 measurement Methods 0.000 claims abstract description 10
- 230000035764 nutrition Effects 0.000 claims abstract description 9
- 239000011777 magnesium Substances 0.000 claims abstract description 7
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 7
- 229910052710 silicon Inorganic materials 0.000 claims abstract description 7
- 239000010703 silicon Substances 0.000 claims abstract description 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 6
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims abstract description 5
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims abstract description 3
- 235000005282 vitamin D3 Nutrition 0.000 claims abstract description 3
- 239000011647 vitamin D3 Substances 0.000 claims abstract description 3
- 229940021056 vitamin d3 Drugs 0.000 claims abstract description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 26
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 16
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 16
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 14
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 13
- 229910052742 iron Inorganic materials 0.000 claims description 13
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 11
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 11
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 11
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 10
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 10
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 8
- 229960000304 folic acid Drugs 0.000 claims description 8
- 235000019152 folic acid Nutrition 0.000 claims description 8
- 239000011724 folic acid Substances 0.000 claims description 8
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 229910052711 selenium Inorganic materials 0.000 claims description 7
- 239000011669 selenium Substances 0.000 claims description 7
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 229960003512 nicotinic acid Drugs 0.000 claims description 6
- 235000001968 nicotinic acid Nutrition 0.000 claims description 6
- 239000011664 nicotinic acid Substances 0.000 claims description 6
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 5
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 5
- 229960002685 biotin Drugs 0.000 claims description 5
- 235000020958 biotin Nutrition 0.000 claims description 5
- 239000011616 biotin Substances 0.000 claims description 5
- 235000013312 flour Nutrition 0.000 claims description 5
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 claims description 4
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
- 229930182817 methionine Natural products 0.000 claims description 3
- 229940055726 pantothenic acid Drugs 0.000 claims description 3
- 235000019161 pantothenic acid Nutrition 0.000 claims description 3
- 239000011713 pantothenic acid Substances 0.000 claims description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 2
- -1 L-BETAIN Chemical compound 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 229910052804 chromium Inorganic materials 0.000 claims description 2
- 239000011651 chromium Substances 0.000 claims description 2
- 239000003094 microcapsule Substances 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 229960003581 pyridoxal Drugs 0.000 claims description 2
- 235000008164 pyridoxal Nutrition 0.000 claims description 2
- 239000011674 pyridoxal Substances 0.000 claims description 2
- 235000008151 pyridoxamine Nutrition 0.000 claims description 2
- 239000011699 pyridoxamine Substances 0.000 claims description 2
- 235000008160 pyridoxine Nutrition 0.000 claims description 2
- 239000011677 pyridoxine Substances 0.000 claims description 2
- 229960003495 thiamine Drugs 0.000 claims description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims 2
- 229940005561 1,4-benzoquinone Drugs 0.000 claims 1
- 241000207199 Citrus Species 0.000 claims 1
- 244000007835 Cyamopsis tetragonoloba Species 0.000 claims 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims 1
- 229940087168 alpha tocopherol Drugs 0.000 claims 1
- 229960004050 aminobenzoic acid Drugs 0.000 claims 1
- 229960005069 calcium Drugs 0.000 claims 1
- 235000021466 carotenoid Nutrition 0.000 claims 1
- 150000001747 carotenoids Chemical class 0.000 claims 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 1
- 229960001231 choline Drugs 0.000 claims 1
- 229940107218 chromium Drugs 0.000 claims 1
- 235000020971 citrus fruits Nutrition 0.000 claims 1
- 238000002474 experimental method Methods 0.000 claims 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims 1
- 229960000367 inositol Drugs 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- 235000019136 lipoic acid Nutrition 0.000 claims 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims 1
- 229910052750 molybdenum Inorganic materials 0.000 claims 1
- 239000011733 molybdenum Substances 0.000 claims 1
- 229960003975 potassium Drugs 0.000 claims 1
- 229960002477 riboflavin Drugs 0.000 claims 1
- 239000002151 riboflavin Substances 0.000 claims 1
- 235000019192 riboflavin Nutrition 0.000 claims 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 claims 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 1
- 239000011721 thiamine Substances 0.000 claims 1
- 235000019157 thiamine Nutrition 0.000 claims 1
- 229960002663 thioctic acid Drugs 0.000 claims 1
- 229960000984 tocofersolan Drugs 0.000 claims 1
- 229910052720 vanadium Inorganic materials 0.000 claims 1
- 229940045605 vanadium Drugs 0.000 claims 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 claims 1
- 235000004835 α-tocopherol Nutrition 0.000 claims 1
- 239000002076 α-tocopherol Substances 0.000 claims 1
- 125000003810 γ-tocopherol group Chemical group 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 abstract description 2
- 150000001945 cysteines Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 description 26
- 210000004209 hair Anatomy 0.000 description 22
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 19
- 239000011782 vitamin Substances 0.000 description 17
- 229940088594 vitamin Drugs 0.000 description 14
- 229930003231 vitamin Natural products 0.000 description 14
- 235000013343 vitamin Nutrition 0.000 description 14
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 12
- 229960003284 iron Drugs 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 150000003722 vitamin derivatives Chemical class 0.000 description 11
- 239000011573 trace mineral Substances 0.000 description 10
- 235000013619 trace mineral Nutrition 0.000 description 10
- 229930003427 Vitamin E Natural products 0.000 description 9
- 231100000360 alopecia Toxicity 0.000 description 9
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 9
- 230000003779 hair growth Effects 0.000 description 9
- 235000019165 vitamin E Nutrition 0.000 description 9
- 239000011709 vitamin E Substances 0.000 description 9
- 229930003779 Vitamin B12 Natural products 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 235000019163 vitamin B12 Nutrition 0.000 description 8
- 239000011715 vitamin B12 Substances 0.000 description 8
- 229940046009 vitamin E Drugs 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 6
- 229930003268 Vitamin C Natural products 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000019158 vitamin B6 Nutrition 0.000 description 6
- 239000011726 vitamin B6 Substances 0.000 description 6
- 235000019154 vitamin C Nutrition 0.000 description 6
- 239000011718 vitamin C Substances 0.000 description 6
- 229940011671 vitamin b6 Drugs 0.000 description 6
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 5
- 244000303965 Cyamopsis psoralioides Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 235000017471 coenzyme Q10 Nutrition 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 206010016256 fatigue Diseases 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 210000004761 scalp Anatomy 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000032823 cell division Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000011593 sulfur Chemical group 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 235000006109 methionine Nutrition 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 206010048259 Zinc deficiency Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- MTJGVAJYTOXFJH-UHFFFAOYSA-N 3-aminonaphthalene-1,5-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(N)=CC(S(O)(=O)=O)=C21 MTJGVAJYTOXFJH-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 102000040350 B family Human genes 0.000 description 1
- 108091072128 B family Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- MBMLMWLHJBBADN-UHFFFAOYSA-N Ferrous sulfide Chemical compound [Fe]=S MBMLMWLHJBBADN-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 1
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 1
- 102000005298 Iron-Sulfur Proteins Human genes 0.000 description 1
- 108010081409 Iron-Sulfur Proteins Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010056677 Nerve degeneration Diseases 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 201000010829 Spina bifida Diseases 0.000 description 1
- 208000006097 Spinal Dysraphism Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- CPGKMLVTFNUAHL-UHFFFAOYSA-N [Ca].[Ca] Chemical compound [Ca].[Ca] CPGKMLVTFNUAHL-UHFFFAOYSA-N 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000037326 chronic stress Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 101150107521 eat-20 gene Proteins 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 229940124563 hair growth stimulant Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 150000002742 methionines Chemical class 0.000 description 1
- UEQANLFPOFICBH-UHFFFAOYSA-N methylseleninic acid Chemical compound C[Se](O)=O UEQANLFPOFICBH-UHFFFAOYSA-N 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000008811 mitochondrial respiratory chain Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 208000026721 nail disease Diseases 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 235000021085 polyunsaturated fats Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000037333 procollagen synthesis Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 150000004059 quinone derivatives Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000003813 thin hair Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 208000002670 vitamin B12 deficiency Diseases 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/25—Silicon; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Birds (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pediatric Medicine (AREA)
- Physiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明涉及包含L‑半胱氨酸和锌的口服生发剂或膳食补充剂(100,100a‑100c),所述生发剂或膳食补充剂(100,100a‑100c)包含铜,钙,镁,硅和胆钙化醇,通过测试和/或测量和/或问卷评估(A‑H)确定构成生发剂或膳食补充剂(100,100a‑100c)的物质或物质组合物(S‑Z)的剂量,以适应女性顾客或男性顾客(200,200a‑200d)的个体有机营养供应需求。
Description
本发明涉及一种生发剂,其目的不是外用于头皮而是用于口服,同时可以当作膳食补充剂。
一些已知的口服生发剂,其基本思路是改善有机体的供应和所需的酸,维生素,矿物质,微量元素等的新陈代谢以对头发生长产生积极的影响。
例如,已经在市场上存在很长时间的是一种含有L-半胱氨酸,含硫的蛋白氨基酸,以及小米果实总提取物和泛酸钙的生发剂。然而,这种生发剂的缺点在于它只涵盖了负责头发健康生长所需全部物质非常窄的范围。此外,组合物也未按个体的需求区分。
另一种口服生发剂,例如 HairPlus。这种生发剂的成分中含有更广泛的必需和有益的物质,除了已经提及的物质外,还添加了酵母,生物素,维生素E,氨基酸,铁,锌等。但这种生发剂也不是个性化的。
一般来说,特别是从经济效益比的角度来看,当一个效率不高,未区分需求的“制剂”被投放到市场上时,是有缺陷的。如果上市成功,也是相当偶然的。
这种以标准或单一制剂形式“已出厂”的未区分需求的生发剂,不仅对于通常是必需的但相当昂贵的已有的物质或物质组合物,还是对于它们的剂量而言,都是有缺陷的。即使女性顾客或男性顾客会个别依赖相对增加剂量的特定物质或物质组合物,但与其他的物质或物质组合物相比,它们只保持在一般合理的和相对较少的水平。
含有激素活性物质或物质组合物的生发剂也是有缺陷的。例如,药物中的活性物质非那雄胺,一旦开始服用,就需要终生保持这种剂量。否则情况就会比原来的初始阶段更坏。此外,这种生发剂通过长期抑制二氢睾酮水平(DHT)来介入激素平衡,具有相当负面的副作用,不适合女性。
此外,还有含有活性物质阿法雌二醇的泛曲坦,将尝试用非激素但准医学或化学方法恢复发根。
PantovigarN也可口服,并尝试通过维生素B和半胱氨酸改善营养供应,从而促进头发角蛋白的构建。
此外,还有由Oxford Biolabs开发的胶囊,以的名称销售,作为针对斑秃的药物申请了专利。在撰写本专利申请时该专利尚未公布,其描述了与天然能量激发物质(CarnipurTM酒石酸盐)组合的强力代谢兴奋剂(钾,烟酸和支链氨基酸,例如缬氨酸,亮氨酸和异亮氨酸)。这种组合物旨在阻止脱发并促进分子水平的头发生长。但是,对女性或男性顾客而言,该药物也不是“个性化”的。
本发明的目的是提供一种生发剂或营养膳食补充组合物,其具有进一步改进的基础组合物,并且其特点和应用是可以根据女性顾客或男性顾客的个体需要而变化和/或调整。
依据本发明,首先的解决方案是基础版本的生发剂组合物包含以下基础物质或基础物质组合物:
-L-半胱氨酸
-锌
-铜
-钙
-镁
-硅
-维生素D3。
如一开始已经提到的,L-半胱氨酸是含硫的蛋白氨基酸和头发角蛋白的基础结构,因此是头发和指甲的重要结构元素。由于含硫,L-半胱氨酸可以结合重金属离子,这又会引发脱发。L-半胱氨酸与其他氨基酸(谷氨酰胺,甘氨酸)一起参与了谷胱甘肽的构建,其是人体最重要的抗氧化剂之一,有利于维生素C和E的利用。谷胱甘肽也抑制炎症反应并刺激白细胞和白细胞三烯的产生。人体肝脏可以合成体内的L-半胱氨酸,但也必须通过饮食吸收,每天需要约1,400毫克。通常体内合成的L-半胱氨酸不能满足需求,因为某些疾病如白内障或关节炎或其他慢性疾病,甚至饮食或压力或体力消耗会增加它的需求。作为食物制备过程的一部分,当食物长时间保持在水中甚至煮沸时,水溶性的L-半胱氨酸被冲刷掉也是一个更加严重的事实。
另一方面,微量元素锌参与人类生物体的细胞分裂,换言之,通常参与生长与细胞和皮肤的再生,胰岛素存储,蛋白质合成,精子产生和免疫系统。锌通常参与激素代谢,在应激过程中对中枢神经系统有积极作用,调节酸碱平衡,有助于转移重金属。锌的缺乏可以引发脱发增加,更糟的是引发皮肤易发炎症和免疫系统的减弱。锌缺乏特别是素食者的问题,因为锌主要包含在肉,奶酪,牛奶和鸡蛋中。当饮食中蛋白质低时,谷物产品中所含的锌不太容易被肠道吸收。当与含铁制剂同时服用时,锌在肠道内的摄取被恶化。
本发明的上述的生发剂的基础组合物还包括铜。微量元素铜影响胶原蛋白的构建,从而确保皮肤组织,结缔组织和神经组织以及血管的收紧。此外,微量元素铜涉及黑色素的形成,头发,皮肤和眼睛的颜色。铜缺乏可能会引发灰头发。此外,铜严重影响延缓老化过程的内源性抗氧化剂的形成。
另一方面,钙不再是人体的微量元素,而是多量元素,也就是每公斤体重超过50毫克。人体钙总量为1-1.1公斤,钙是人体中最丰富的矿物质。其中99%的钙发现于骨骼和牙齿中,但身体的钙也参与刺激肌肉和神经,代谢糖原和氨基酸,细胞分裂以及激活一些酶和激素。对于成年人,建议每日大概的摄入量为1,000毫克。值得注意的是,当饮食中蛋白质特别丰富时,对钙的需求量也增加。
此外,镁是必不可少的物质之一,因为它对于所有有机体是必不可少的。必须通过食物和饮用水每天摄入足够的量(约300毫克),并在小肠上部内进行吸收。成年人的身体含有约20克的镁,其作为酶组分或辅酶参与约300个酶反应。此外,作为免疫系统中的第二信使,游离镁离子影响细胞膜的潜力和功能。它们稳定了兴奋的肌肉和神经细胞以及自主神经系统细胞的静态电位。镁是肌肉和结缔组织的松弛剂。镁缺乏引发不安,紧张,烦躁,头痛,注意力缺乏,疲劳,无力感,心律失常,肌肉痉挛,至少,这种恶劣的营养供应状况会影响头发生长。
硅是骨形成细胞的主要元素,也是软骨,结缔组织,骨组织,皮肤,头发和指甲等的重要结构成分。在脱发期间观察到低的发-硅值。铝的慢性应激似乎削弱了硅的生物利用度。
维生素D3又称为胆钙化醇是人类生物体必需的,尤其是,它通过形成蛋白质屏障确保将钙穿过肠壁的输送以吸收更多量的钙。维生素D3是唯一的其生物活性形式是在生物体中用途广泛的激素的维生素。除了对骨骼和牙齿的发育,在许多其他方面,对于通过支持白细胞抵抗感染的功能的免疫系统也是重要的。由于现代社会的地方性光缺乏,皮肤中维生素D3的有机合成不足,因此德国营养学会(DGE)为成人提供了每日要食用20微克维生素D3的指南,以满足营养需要。一个更加严重的事实是,不仅防晒霜,而且目前几乎所有的日霜都过滤UV-B和UV-A。
这些基础物质或基础物质组合物的剂量可以根据个人测试和测量结果,也可以根据调查问卷的评估结果,针对女性或男性顾客个体有机营养素供应需求进行变化和调整。
本发明基于以下基本原则:一个人的头发当然可以被赋予某些特定的身体功能或有机的“目的”,但是这些对于生物体并不至关重要。例如,在因严寒而死亡的情况下,停止向四肢或不具有重要功能的器官供血,最后仅仅是对心脏和脑供血。类似地,持续营养缺乏时,有机体首先对身体的重要器官和部位起反应,确定可用营养物质的优先次序,并且头毛生长被给予较低或甚至是最后的优先级。
第二个基本思想是少数脱发是遗传的,而多数是由生活习惯引起的,并且吸收或重复利用某些营养物质的能力更好或更差。此外,根据本发明适用的生发剂是基于以下事实:约80%的男性,仅约38%的女性受脱发影响。因此,至少在性别方面,有必要根据两性的不同前提条件或者进一步根据个体需求,调整生发剂。
此外,本发明的生发剂或膳食补充剂基于以下事实:现今生活中食物的维生素和营养成分减少约30%。同时,更加紧张和忙碌的生活方式需要增加维生素,微量元素和矿物质,氨基酸和准氨基胺等重要物质的摄取。
此外,本发明的生发剂基于分子矫正医学的发现。此后,只有当大量不同的重要物质确保了不同和协调的剂量时,才能在生物体内发生最佳的新陈代谢。在所需的二十多种微量营养素中,缺少一种就可能会减缓甚至阻止整个新陈代谢。因此,本发明的生发剂的组合物不仅满足于个体的物质或物质组合物以及通常谨慎推荐的最小剂量,而且优选含有身体所需的许多或全部物质,没有一种或另一种的剂量非常高。
根据本发明的生发剂的另一种实施方案的变体,除了包含第[0012]段中所列的基础物质或基础物质组合物外,还含有维生素E。维生素E是具有抗氧化作用的脂溶性物质的综合术语,最常见于生育酚和生育三烯酚的形式。维生素E有助于免疫系统去除环境中的氧化影响,排出有毒物质和破坏细菌。还观察到维生素E的需求随着饮食中含有多不饱和脂肪酸的量的增加而增加。本发明的生发剂的组合物最终含有维生素E,因为已经认识到维生素E促进头皮的血液循环,从而增强了头发的固着。此外,维生素E是合成头发各种营养素所必需的。
此外,根据本发明的生发剂或膳食补充剂组合物的另一个实施方案的变体,除了第[0012]段和/或第[0012]和[0025]段所列的基础物质或基础物质组合物之外,还包含维生素C或抗坏血酸。这是基于维生素C有助于解毒的知识,例如它作为应激管理剂,是一种有效的抗氧化剂(“自由基清除剂”),从而为头发生长提供更多营养素。维生素C也显著地参与胶原蛋白的生成,并且也改善了头发的结构。
根据本发明的生发剂的另一个实施方案的变体,除了迄今为止公开的基础物质或基础物质组合物之外,还包含生物素或维生素H或维生素B7。这是由于生物素显著地参与代谢活化和细胞生长的原因,但是,其缺点可能导致脱发增加。
根据本发明的生发剂的另一种组合物变体还含有必不可少的L-甲硫氨酸,像L-半胱氨酸一样也是由形成L-半胱氨酸的含硫的蛋白氨基酸形成的。L-甲硫氨酸参与原骨胶原的合成,因此对于头发形成是重要的。
根据本发明的生发剂的另一种优选的组合物的变体还包括泛酸,也称为维生素B5。它是B族维生素中的水溶性维生素,并且涉及碳水化合物,脂肪,氨基酸的合成和分解以及胆固醇的合成,这又是形成类固醇激素所必需的。泛酸缺乏可能会引发疲劳,失眠,抑郁,耳聋,肌肉酸痛,贫血,免疫缺陷和胃痛,形成一种普遍的恶劣状况,从而减损头发生长所需的营养素供应。
根据本发明的生发剂或膳食补充剂组合物的另一优选实施方案的变体,除了所公开的基础物质或基础物质加上一种物质或一种可选的物质组合物或加上所有可选的物质的组合物之外还含有铁。铁是一种必需的微量元素,涉及血液形成和氧气输送,氧气存储和电子传递。此外,铁是许多酶中的铁-硫复合物的组分。已经认识到,不仅女性因为月经和生产普遍缺铁,而且在运动员中也常见。在根据本发明的生发剂或含铁的膳食补充剂组合物中,同时摄取维生素C显著地增加铁的吸收速率,但是奶制品,咖啡或红茶抑制它们。
特别地,生发剂或膳食补充剂组合物的另一优选实施方案的变体中,除了所公开的基础物质或基础物质加上一种物质或一种可选的物质组合物或加上所有可选的物质组合物,维生素B6是活性维生素磷酸吡哆醛的三种前体,分别称为吡哆醇,吡哆醛和吡哆胺。维生素B6对于氨基酸代谢是必需的,并且在约100个酶反应中起辅酶作用。缺乏维生素B6与食欲不振,腹泻,呕吐,皮炎,生长障碍,贫血,神经退化,不规则间隔抽搐和焦虑症有关。维生素B6的需求与蛋白质增益成正比,德国营养学会(DGE)建议,妇女每天服用1.6毫克,男性1.8毫克。
根据本发明的生发剂或膳食补充剂组合物的另一优选实施方案的变体,除了所公开的基础物质或基础物质加上一种物质或一种可选的物质组合物或加上所有可选的物质的组合物之外,还含有维生素B12或以中心原子钴命名的钴胺素。在人类生物体中维生素B12对于细胞分裂和血液形成以及神经系统的功能是重要的。人体不能自身产生维生素B12,因此必须通过食物获得。这是通过肉和内脏的摄入来保证的,并且必须通过乳制品和鸡蛋或藻类的摄入来增加获取。维生素B12的缺乏可引发血细胞减少的疾病和脊髓炎,背部或骨髓的炎症。此外,近年来维生素B12缺乏与其他疾病(例如痴呆和神经病变)之间可能有联系的证据增加了。一般来说,血清中维生素B12的浓度较低在老年人中更为常见。成年人维生素B12供应不足的第一迹象可能是刺痛,感觉手脚冷,疲惫无力,注意力缺乏,甚至精神病。成年人每日最低需求约为3.0微克,怀孕和哺乳期妇女为3.5-4.0微克。
根据本发明的生发剂或膳食补充剂组合物的另一优选实施方案的变体,除了所公开的基础物质或基础物质加上一种物质或一种可选的物质组合物或加上所有可选的物质的组合物之外,还包含硒。对于所有形式的生命,硒都是必需的微量元素,由于其与氧的反应性高,因此可以保护细胞膜免受氧化破坏。此外,硒及其化合物在产生甲状腺激素的过程中起重要作用。然而,只有在非常狭窄和精确的剂量范围内才能观察到硒的积极作用。有研究怀疑每天服用200微克硒引发2型糖尿病。而在电子,玻璃和涂料行业的员工中,摄入超过日剂量400微克的人员,会有恶心呕吐,指甲变化,周围神经病变,疲劳和脱发等中毒症状。
根据本发明的生发剂的另一组合物变体还含有烟酸或尼克酸,其是来自复合维生素B的另一种维生素。它是被发现于所有活细胞中并且储存在肝脏中的固体结晶。它对于蛋白质,脂肪和碳水化合物的代谢是至关重要的,对于皮肤,肌肉,神经和DNA的再生也是重要的。它还改善头皮的血液循环,成人平均消耗6.6毫克烟酸可以为其细胞,组织和器官产生1,000千卡能量。因此,妇女每日需要13至15毫克,而男性每天需要15至20毫克。
根据本发明的生发剂的另一个实施方案的变体,除了上述的基础物质或可选的物质之外,还包含叶酸,它还以维生素B9的惯用名称和B族光敏维生素而为人所知。叶酸参与DNA结构单元的合成,并在细胞分裂中起决定性作用。其是人体必需的,不能自身产生。叶酸缺乏可以引发贫血,神经管发育缺陷,如胚胎发育中的脊柱裂或脑畸形。根据RDA(每日推荐剂量)或营养供应的D-A-CH参考值的推荐每日剂量为200微克。在一些国家,例如瑞士,有法定义务添加叶酸。
根据本发明的生发剂或膳食补充剂另一优选的组合物变体,除基础物质或含有可选物质的基础物质的任何组合物之外,还包括辅酶Q10,也称为泛醌10。它是与维生素K和维生素E结构相关的醌衍生物,部分通过食物吸收,也可由身体自身产生。Q10对于人体在细胞中将食物能量转化为体内能量(ATP)至关重要。Q10是细胞线粒体呼吸链的重要辅助因子,也是作为自由基清除剂在应激和退化过程中最重要的亲脂性抗氧化剂。永久性Q10缺乏症是罕见的,但是为了避免或补偿缺乏,大多数科学家建议每日剂量为30-200毫克的辅食。
根据本发明的生发剂或膳食补充剂的另一优选组合物变体,除基础物质或含有可选物质的基础物质的任何组合物之外,还包括ω-3脂肪酸。其是人类营养的必需物质,不能由身体自身产生。它能降低心血管风险,预防癌症,抑制炎症,预防与年龄相关的退行性疾病和痴呆症。欧洲食品安全局(EFSA)和德国营养学会(DGE)特别地建议每日摄入250毫克的ω-3脂肪酸,特别是ω-3脂肪酸中的二十二碳六烯酸(DHA)和二十碳五烯酸(EPA)。ω-3脂肪酸优选通过微胶囊以粉状物混合,或与本发明的含有ω-3脂肪酸的粉状生发剂或膳食补充剂是一致的。
根据本发明的生发剂的优选组合物,还包含与所公开的物质和物质组合物结合的瓜尔豆粉。瓜尔豆粉由瓜尔豆的种子产生,主要由长链碳水化合物组成,特点是以单糖甘露糖和半乳糖的形式组成。长链化合物可以结合非常大量的水。观察发现,这和本发明的生发剂或膳食补充剂的物质和物质组合物能更好地被输送到小肠中的原因可能是粘稠的是一致的。与胃或十二指肠相反,在小肠中,物质和物质组合物的摄取几乎增加了100%,且没有不良的相互作用。另外,瓜尔豆粉具有积极的副作用,具有肠道保健作用。根据本发明,瓜尔豆粉有缓凝剂的功能,以这种方式允许在最有效的地方吸收营养素。
在有可能对瓜尔豆粉过敏的情况下,根据本发明上述的优选生发剂的组合物优选选自刺槐豆胶。
考虑到所有这些发现和发明,根据本发明的可选和示例性的完整版本的生发剂或膳食补充剂,例如对于一个成年人的示例,不一定是累积的物质或物质组合物,但同样具有以下优选的日剂量和日剂量范围:
以下被认为是测试和测量的项目:血液,尿液,肌酐,唾液,头发,粪便和呼气测试,最后一项特别用于确定呼出气体的酸含量或PH值。下面描述的根据本发明的生发剂的变体基于以下事实:人类生物体的过度酸化会抑制许多维生素,微量元素,矿物质和氨基的摄取。
上述血液试验优选由以下单次试验组成:血细胞数量,血细胞减少,甲状腺和肾功能参数,血清铁,铁结合能力,全血锌和硒,血清钙和全血钙,转氨酶和免疫球蛋白E(IgE)-水平。
作为问卷调查或记录顾客数据的指南,例如可以问询性别,身高,体重,年龄,健康状况,服用的药物和其他食物,饮酒和生活习惯。此外,例如,还可询问顾客关于生发的偏好。
根据本发明,生发剂的基础剂量根据测试和测量的结果进行调整,但也可选择仅由调查问卷的答案决定。因此,例如,与女性指定服用20.0毫克的锌不同,男性每天剂量为25.0毫克或甚至30.0毫克。与女性相比,男性的锌剂量会增加,因为他们有增加精子的需求。
此外,与男性仅指定1.0毫克不同,可以为女性指定3.0毫克日剂量的γ-氨基丁酸。γ-氨基丁酸GABA对于女性的增加可能由于她们遭受经前期综合症,这可以通过服用GABA来缓解。此外,与男性不同,女性蛋白质储备较少。这就是为什么她们需要更多的GABA。另一方面,GABA在维生素B6和L-半胱氨酸的结合上具有积极的增强作用。,男人经常是全秃或半秃,因此会增加对L-半胱氨酸的需求,这就是为什么他需要更少的GABA。对于那些每周饮酒超过三次的人,会增加GABA的需求,因为GABA可以通过其神经镇静作用减少对酒精的渴望。
此外,由于性别不同,根据本发明也可以指定男子只需1.0毫克的铁,而女性2.5毫克。在某种程度上男性可以减少铁的指定,他们没有月经期间铁的损失,并且从饮食习惯上,男性平均消费的肉比女性多。
根据身高和体重,本发明还指定添加每公斤体重13.0毫克L-甲硫氨酸的组合物。
根据顾客的年龄,依年龄分级指定维生素B12的剂量,其基本上可以在1.0-1,000.0微克的范围内移动,但优选范围在20.0微克至50.0微克之间,优选为35.0微克。此外,年龄在18-35岁之间优选为20.0微克,年龄在35-60岁之间为35.0微克,年龄在60-99岁之间为50.0微克。
如果患有甲状腺功能障碍,碘的量可以增加到200.0微克。
如果已经患有癌症,表中所示的10.0毫克维生素B6的优选量可以增加到25.0毫克。此外,将叶酸的量从0.2毫克加至0.4毫克。Q10的范围可以为100.0毫克至150.0毫克,GABA为1.0毫克至2.0毫克。此外,维生素B12可以从35.0微克增加到50.0微克。
如果患有糖尿病,可以把L-半胱氨酸的优选量从表中所示的1000毫克减少至400.0毫克。此外,维生素B1也可以从5.0毫克增加到50.0毫克,维生素B6从10.0毫克增加到50.0毫克。此外,铬从50.0微克增加到200.0微克。
在有心理或身体压力的情况下,维生素C可以从1,500.0毫克增加到2,000.0毫克,叶酸可以从200.0微克增加到800.0微克。
如果一位女性顾客每星期运动超过三次,可以把锌的优选剂量从表中所示的25.0毫克增加到30.0毫克。如果男性同样每星期运动超过三次,可以增加到40.0毫克。
如果女性顾客每周饮酒超过三次,锌的优选剂量可以从表中所示的25.0毫克增加到30.0毫克,GABA可以从1.0毫克增加到3.0毫克。烟酸的剂量也可以从50.0毫克增加到300.0毫克。
对于经常吸烟的顾客来说,香烟烟雾可能会引发锌缺乏,也可能引发铜过量甚至铜中毒。因此,对于吸烟者,铜的优选量可以从表中所示的2.0毫克减少1.0毫克。此外,在吸烟的情况下,维生素C可以从1,500.0毫克增加2,000.0毫克。此外,叶酸从0.2毫克增加至0.4毫克,维生素B6从10.0毫克增加至25.0毫克,维生素B12从35.0微克增加至40.0微克。此外,硒也可以从200.0微克增加到250.0微克。
服用根据本发明的生发剂或膳食补充剂的同时或之前,可以有选择性地为肠道或生物体脱酸。同时,可以以螯合的形式加入硅,锌和铁,后两种微量元素是优选。
如果需要,可以先康复肠道以最佳地吸收所述物质和物质组合物。
然而,原则上,也可以通过肌内或皮下或静脉注射给予本发明的生发剂或膳食补充剂组合物并且通过积存注射给予某些特定的物质。
正如本申请所描述的以及将要描述的进一步的实施方案的变体,本发明的生发剂通常同样适合作为膳食补充剂。已经观察到,本发明的生发剂或膳食补充剂组合物对于指甲健康和强力的生长以及对于头皮的健康来说是有益的。它也对糖尿病和抗心肌梗死有积极的作用。
本发明的生发剂或膳食补充剂优选生产或提供含有妇女平均剂量的一般性的基础版本和含有男性平均剂量的一般性的基础版本。在对测试和测量以及调查问卷进行评估之后,这个基础版本能够补充所需的不同物质或不同剂量而成为本发明的个性化的特制的生发剂或膳食补充剂。
本发明所公开的的生发剂或膳食补充剂组合物的不同实施方案的变体可以根据需要相互组合任选的物质。
本申请公开了一种个性化的辅食调整方法,包括以下步骤:
a)-提供女性平均剂量的膳食补充剂通用版本;
b)-提供男性平均剂量的膳食补充剂通用版本;
c)-女性顾客或男性顾客回答调查问卷;
d)-如有必要,进行测试和测量;
e)-通过问卷评估和测试和测量确定不同物质和不同剂量;
f)-为女性顾客选择女性膳食补充剂通用版本;
g)-为男性顾客选择男性膳食补充剂通用版本;
h)-通过添加确定的不同物质和不同剂量,为个体女性顾客或个体男性顾客调整选定的膳食补充剂版本。
本发明的生发剂或膳食补充剂具有以下优点,其中许多是经过受试者的证明:
-生发剂或膳食补充剂是为顾客个性化订制的;
-确定了缺少的重要物质;
-含有所有必需的重要物质,为缺少的物质提供最高剂量;
-耐受性好;
-作为生发剂同样适合作为膳食补充剂;
-增加健康和幸福;
-受试者感觉不太累,有更多的精力;
-刺激头发生长,头发数量增多,更加健康有韧劲;
-头发变得有光泽;
-稀疏的头发变得浓密;
-脆硬的头发变柔顺;
-头皮鳞屑恢复了健康;
-头发在一个生长阶段加速生长。
根据本发明的生发剂的进一步或优选的实施方案形成从属权利要求的主题。
参考清单是公开的不可分割的部分。
通过附图以象征性的和示例性的方式说明本发明的更详细的细节。它是图解的和示例的显示各个部分彼此之间的关系,不是真实的比例,。相同的参考符号表示相同的对象或组分,具有不同标记的参考符号表示功能相同或相似的对象或组分。
图1是本发明的生发剂或膳食补充剂个性化调整实施例的示意图。
图1中,200是由于头发生长稀疏而寻求帮助的女性顾客1.第一阶段I是获取顾客或确定需求300,包括测试,测量和问卷评估A-H。
在调整制剂400的第二阶段II中,第一种生发剂100含有按照测试A-C的结果而选择的物质或组合物物S-U。作为实例,第二种生发剂100a,含有按照测试D-F的结果而选择的物质或组合物物V-X。进一步的实例是第三种生发剂100b含有按照测试G的结果而选择的物质或组合物Y,以及按照测试H的结果而选择的物质或组合物Z,以及按照测试A的结果而选择的物质或组合物S。作为实例,第四种即最后一种生发剂实例100c含有按照测试D的结果而选择的物质或组合物V,以及按照测试F的结果而选择的物质或组合物X,以及按照测试G的结果而选择的物质或组合物Y。
第三阶段III展示出第一阶段的女性顾客200通过服用生发剂100确实已经“变成“女性顾客200a,但是头发生长还没有很成功地改善。同样的情况对应于通过服用生发剂100a和100c,“变成”女性顾客200b和200d。另一方面,在服用生发剂100b的情况下,女性顾客200已经“变成“头发强烈和大量生长2的女性顾客200c。每种情况从阶段I到阶段III的时间需要几个月。
参考符号列表
1-头发生长稀疏
2-头发强壮,大量地生长
100,100a-100c–生发剂,膳食补充剂
200,200a-200d-女性顾客
300-获取顾客,确定需求
400-调整制剂
I-第一阶段
II-第二阶段
III-第三阶段
A-H-测试,测量,问卷评估
S-Z-物质或物质组合物
Claims (18)
1.口服的生发剂或膳食补充剂(100,100a-100c),包含L-半胱氨酸和锌,其特征在于所述生发剂或膳食补充剂(100,100a-100c)包含铜,钙,镁,硅和胆钙化醇。
2.根据权利要求1所述的生发剂或膳食补充剂(100,100a-100c),其特征在于通过试验和/或测量和/或问卷评估(A-H)确定构成所述生发剂膳食补充剂(100,100a-100c)的物质或物质组合物(S-Z)的剂量,以适应女性顾客或男性顾客(200,200a-200d)的个体有机营养供应需求。
3.根据前述任一权利要求的生发剂或膳食补充剂(100,100a-100c),其特征在于所述的生发剂或膳食补充剂(100,100a-100c)包含α-生育酚和γ-生育酚形式的天然维生素E。
4.根据前述任一权利要求的生发剂或膳食补充剂(100,100a-100c),其特征在于所述生发剂或膳食补充剂(100,100a-100c)包含抗坏血酸。
5.根据任一前述权利要求的生发剂或膳食补充剂(100,100a-100c),其特征在于所述生发剂或膳食补充剂(100,100a-100c)包含生物素。
6.根据前述任一权利要求的生发剂或膳食补充剂(100,100a-100c),其特征在于所述生发剂或膳食补充剂(100,100a-100c)包含L-甲硫氨酸。
7.根据前述任一述权利要求的生发剂或膳食补充剂(100,100a-100c),其特征在于所述生发剂或膳食补充剂(100,100a-100c)包含泛酸。
8.根据前述任一权利要求的生发剂或膳食补充剂(100,100a-100c),其特征在于所述生发剂或膳食补充剂(100,100a-100c)包含铁。
9.根据前述任一权利要求的生发剂或膳食补充剂(100,100a-100c),其特征在于所述生发剂或膳食补充剂(100,100a-100c)包含吡哆醇和/或吡哆醛和/或吡哆胺。
10.根据前述任一利权要求的生发剂或膳食补充剂(100,100a-100c),其特征在于所述生发剂或膳食补充剂(100,100a-100c)包含钴胺素。
11.根据前述任一权利要求的生发剂或膳食补充剂(100,100a-100c),其特征在于所述生发剂或膳食补充剂(100,100a-100c)包含硒。
12.根据前述任一权利要求的生发剂或膳食补充剂(100,100a-100c),其特征在于所述生发剂或膳食补充剂(100,100a-100c)包含烟酸。
13.根据前述任一权利要求的生发剂或膳食补充剂(100,100a-100c),其特征在于所述生发剂或膳食补充剂(100,100a-100c)包含叶酸。
14.根据前述任一权利要求的生发剂或膳食补充剂(100,100a-100c),其特征在于所述生发剂或膳食补充剂(100,100a-100c)包含泛醌-10。
15.根据前述任一权利要求的生发剂或膳食补充剂(100,100a-100c),其特征在于所述生发剂或膳食补充剂(100,100a-100c)包含ω-3脂肪酸,所述ω-3脂肪酸与粉状的生发剂或膳食补充剂(100,100a-100c)组合物以微胶囊的形式混合。
16.根据前述任一权利要求的生发剂或膳食补充剂(100,100a-100c),其特征在于,所述生发剂或膳食补充剂(100,100a-100c)包含瓜尔豆粉。
17.根据前述任一权利要求的生发剂或膳食补充剂(100,100a-100c),其特征在于,所述生发剂或膳食补充剂(100,100a-100c)包含天然类胡萝卜素,类维生素A,硫胺素,核黄素,铬,碘,锰,钼,钒,钙,钾,α-硫辛酸,胆碱,肌醇,L-肉毒碱,对氨基苯甲酸,γ-氨基丁酸,西来林和柑橘类生物类黄酮。
18.根据前述权利要求1-17中任一权利要求的顾客特定的调整膳食补充剂(100,100a-100c)的方法,其特征在于,包括以下步骤:
a)-提供女性平均剂量的膳食补充剂通用版本;
b)-提供男性平均剂量的膳食补充剂通用版本;
c)-女性顾客(200,200a-200d)或男性顾客回答调查问卷(A-H);
d)-如有必要,进行测试和测量(A-H);
e)-通过问卷评估(A-H)和测试和测量(A-H)确定不同物质和不同剂量;
f)-为女性顾客选择膳食补充剂通用版本;
g)-为男性顾客选择膳食补充剂通用版本;
h)-通过添加确定的不同物质和不同剂量,为个体女性顾客(200,200a-200d)或个体男性顾客调整(400)选定的膳食补充剂版本。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH02057/14A CH710567A1 (de) | 2014-12-30 | 2014-12-30 | Haarwuchspräparat bzw. Nahrungsergänzungsmittel. |
CHCH02057/14 | 2014-12-30 | ||
PCT/IB2015/060047 WO2016108195A1 (de) | 2014-12-30 | 2015-12-30 | Haarwuchspräparat bzw. nahrungsergänzungsmittel |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107257676A true CN107257676A (zh) | 2017-10-17 |
Family
ID=56284381
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201580076883.7A Pending CN107257676A (zh) | 2014-12-30 | 2015-12-30 | 生发剂或膳食补充剂 |
Country Status (8)
Country | Link |
---|---|
US (2) | US20170368097A1 (zh) |
EP (1) | EP3503865A1 (zh) |
KR (1) | KR20170107471A (zh) |
CN (1) | CN107257676A (zh) |
AU (2) | AU2015373094A1 (zh) |
CH (1) | CH710567A1 (zh) |
SG (2) | SG10202012668RA (zh) |
WO (1) | WO2016108195A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107823619A (zh) * | 2017-12-14 | 2018-03-23 | 陕西顾森健康科技有限公司 | 一种滋养生发及防脱发的中药组合物 |
CN109090249A (zh) * | 2018-08-23 | 2018-12-28 | 李卫平 | 一种辅助养发的羊奶片及其制备方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018145109A1 (en) * | 2017-02-06 | 2018-08-09 | Massachusetts Institute Of Technology | Methods and products related to glutaminase inhibitors |
KR102561482B1 (ko) * | 2021-03-24 | 2023-07-31 | 김형욱 | 탈모방지 및 발모촉진용 약학 조성물 및 이를 포함하는 제품 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991011117A3 (en) * | 1990-02-05 | 1991-09-19 | Univ Texas | Dietary supplements comprising vitamins and minerals |
DE9412374U1 (de) * | 1994-08-01 | 1994-09-22 | Rauch-Petz, Gisela G., Dr., 80803 München | Nahrungsergänzungsmittel |
EP0799578A2 (de) * | 1996-04-03 | 1997-10-08 | Norbert Mag. Fuchs | Elektrolyt-angereicherte Keimlinge enthaltendes Kombinationspräparat |
US6149933A (en) * | 1997-07-10 | 2000-11-21 | Summa Rx Laboratories, Inc. | Dietary supplement for promotion of healthy hair and pigment restoration |
CN1842348A (zh) * | 2004-02-17 | 2006-10-04 | 韦利英特股份公司 | 用于提高活性物质生物利用度的半乳甘露聚糖和/或葡甘露聚糖 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6849613B2 (en) * | 2001-08-29 | 2005-02-01 | Kedar N. Prasad | Multiple antioxidant micronutrients |
US20050106263A1 (en) * | 2003-11-19 | 2005-05-19 | Yucel Donmez | Green tea, multivitamin, mineral and herb based hair and male facial skin formulas |
WO2005079857A1 (de) * | 2004-02-17 | 2005-09-01 | Wheli Inter Ag | Galaktomannane und/oder glucomannane zur erhöhung von wirkstoff-bioverfügbarkeit |
KR101573316B1 (ko) * | 2004-03-29 | 2015-12-01 | 와이어쓰 엘엘씨 | 종합비타민 및 무기물 영양 보충제 |
US20100129467A9 (en) * | 2007-08-31 | 2010-05-27 | Albritton Iv Ford D | Nutritional supplement |
WO2009100271A1 (en) * | 2008-02-07 | 2009-08-13 | Ralph Brown | Prevention of micronutrient deficiencies associated with common disabilities in the over 50 adult |
US20130101569A1 (en) * | 2011-10-15 | 2013-04-25 | Anthony R. Weston | Hair growth stimulant |
-
2014
- 2014-12-30 CH CH02057/14A patent/CH710567A1/de unknown
-
2015
- 2015-12-30 US US15/540,577 patent/US20170368097A1/en not_active Abandoned
- 2015-12-30 KR KR1020177021486A patent/KR20170107471A/ko not_active IP Right Cessation
- 2015-12-30 SG SG10202012668RA patent/SG10202012668RA/en unknown
- 2015-12-30 EP EP15834722.9A patent/EP3503865A1/de active Pending
- 2015-12-30 WO PCT/IB2015/060047 patent/WO2016108195A1/de active Application Filing
- 2015-12-30 CN CN201580076883.7A patent/CN107257676A/zh active Pending
- 2015-12-30 SG SG11201705366TA patent/SG11201705366TA/en unknown
- 2015-12-30 AU AU2015373094A patent/AU2015373094A1/en not_active Abandoned
-
2020
- 2020-06-18 US US16/905,179 patent/US20200316114A1/en not_active Abandoned
-
2021
- 2021-06-22 AU AU2021204218A patent/AU2021204218A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991011117A3 (en) * | 1990-02-05 | 1991-09-19 | Univ Texas | Dietary supplements comprising vitamins and minerals |
DE9412374U1 (de) * | 1994-08-01 | 1994-09-22 | Rauch-Petz, Gisela G., Dr., 80803 München | Nahrungsergänzungsmittel |
EP0799578A2 (de) * | 1996-04-03 | 1997-10-08 | Norbert Mag. Fuchs | Elektrolyt-angereicherte Keimlinge enthaltendes Kombinationspräparat |
US6149933A (en) * | 1997-07-10 | 2000-11-21 | Summa Rx Laboratories, Inc. | Dietary supplement for promotion of healthy hair and pigment restoration |
CN1842348A (zh) * | 2004-02-17 | 2006-10-04 | 韦利英特股份公司 | 用于提高活性物质生物利用度的半乳甘露聚糖和/或葡甘露聚糖 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107823619A (zh) * | 2017-12-14 | 2018-03-23 | 陕西顾森健康科技有限公司 | 一种滋养生发及防脱发的中药组合物 |
CN109090249A (zh) * | 2018-08-23 | 2018-12-28 | 李卫平 | 一种辅助养发的羊奶片及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CH710567A1 (de) | 2016-06-30 |
AU2015373094A1 (en) | 2017-07-27 |
AU2021204218A1 (en) | 2021-07-15 |
EP3503865A1 (de) | 2019-07-03 |
US20170368097A1 (en) | 2017-12-28 |
KR20170107471A (ko) | 2017-09-25 |
US20200316114A1 (en) | 2020-10-08 |
WO2016108195A1 (de) | 2016-07-07 |
SG10202012668RA (en) | 2021-01-28 |
SG11201705366TA (en) | 2017-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Naderi et al. | Recent developments in folate nutrition | |
Feillet et al. | Nutritional issues in treating phenylketonuria | |
Bellows et al. | Water-soluble vitamins: B-complex and vitamin C | |
AU2021204218A1 (en) | Hair Restorer Preparation Or Food Supplement | |
KR20110108399A (ko) | 50세 이상을 위한 정력, 면역성, 눈 및 뼈 건강 개선용 영양 보충물 | |
Shankar | Mineral deficiencies | |
Barnokhon et al. | The importance of enrichment of bakery products with vitamins and minerals on human health | |
Banjari et al. | The question is whether intake of folic acid from diet alone during pregnancy is sufficient | |
Hoffmann et al. | Functional food of animal origin. Meat and meat products | |
BE1006217A6 (fr) | Boisson lactee enrichie de nutriments. | |
CN105596342A (zh) | 一种儿童补铁与维生素的组合物及其制备方法和应用 | |
Dwivedi et al. | Nutrient Requirements in Health and Disease | |
LeMone | Vitamins and minerals | |
US20220249546A1 (en) | Beverage fortified with ferrous bisglycinate | |
SG188628A1 (en) | Trivalent chromium and boron fortifying composition, a hydration supplement, and process for preparing the same | |
JP2019103482A (ja) | パン | |
US20220304971A1 (en) | Beverage fortified with ferrous bisglycinate | |
Khosravi-Darani et al. | Phenylketonuria patients and recent approaches | |
Van Schoor | Vitamin and mineral supplements | |
WO2024144735A1 (en) | A microencapsulated food supplement with probiotic microorganisms | |
EP4072515A1 (fr) | Produit de combinaison, contribuant au bien-etre de la femme enceinte, comprenant epa, dha, des vitamines et des mineraux | |
Capener et al. | Evaluation of a New Glycomacropeptide-Based Protein Substitute in Powdered and Liquid Format in Patients with PKU | |
Samanth | A Synopsis of the Role and Significance of the Chemical Elements in Human Body | |
Code | Great-tasting, chewable zinc tablet | |
SUFFICIENT | PREGLEDNI ČLANCI |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200407 Address after: Zug City Applicant after: SH Electric Power Co.,Ltd. Address before: Ham, Switzerland Applicant before: Simone Heike |
|
TA01 | Transfer of patent application right | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171017 |
|
RJ01 | Rejection of invention patent application after publication |